
Edgar Filing: ELITE PHARMACEUTICALS INC /NV/ - Form 8-K ELITE PHARMACEUTICALS INC /NV/ Form 8-K April 11, 2013 **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K **CURRENT REPORT** PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 10, 2012 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of Company as specified in its charter) Delaware 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer File Number) Identification No.) of incorporation)

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

1

## Edgar Filing: ELITE PHARMACEUTICALS INC /NV/ - Form 8-K



## Edgar Filing: ELITE PHARMACEUTICALS INC /NV/ - Form 8-K

#### **Item 8.01 Other Events**

On April 11, 2012, Elite Pharmaceuticals, Inc. (the "Company") issued a press release to announce that the initial shipment of phentermine HCI capsules 15 mg and 30 mg was made to TAGI Pharma, a wholly owned subsidiary of Precision Dose, triggering a milestone payment under the License, Manufacturing and Supply Agreement.

A copy of the press release is being finished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

### **Item 9.01 Financial Statements and Exhibits**

- a) Not applicable.
- b) Not applicable.
- c) Not applicable.
- d) Exhibits

Exhibit No.	<u>Exhibit</u>

99.1 Press Release dated April 11, 2012

### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# Edgar Filing: ELITE PHARMACEUTICALS INC /NV/ - Form 8-K

Dated: April 11, 2012

# ELITE PHARMACEUTICALS, INC.

By: /s/ Chris Dick

Name: Chris Dick

Title: President and Chief Operating Officer